Early Minimal Residual Disease (MRD) Analysis During Treatment of Philadelphia Chromosome / Bcr-Abl Positive Acute Lymphoblastic Leukemia (Ph + ALL) with the Abl-Tyrosine Kinase Inhibitor STI571 (Glivec) Analysis in Ph + ALL During STI571 Treatment